CC
CLB icon

Cypress Capital’s Core Laboratories CLB Stock Holding History

Cypress Capital’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,722
Closed -$292K – 104
2022
Q2 		$292K Hold
14,722
– – 0.04% 149
2022
Q1 		$466K Hold
14,722
– – 0.06% 152
2021
Q4 		$328K Hold
14,722
– – 0.04% 166
2021
Q3 		$409K Buy
+14,722
New +$448K 0.05% 143

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Cypress Capital's CLB Position: Q3 2022 in Review

Cypress Capital sold out of Core Laboratories (CLB) in Q3 2022, closing a stake of 14,722 shares — an estimated $292K sold.

Cypress Capital first reported a position in CLB in Q3 2021 and held it in 4 quarters. The position peaked at $466K in Q1 2022. 162 funds tracked by Wall St. Rank hold CLB as of Q3 2022.

  • Cypress Capital reported no remaining Core Laboratories position as of Q3 2022 after selling out during the quarter.
  • Cypress Capital sold 14,722 Core Laboratories shares in Q3 2022, an estimated $292K.
  • Cypress Capital first reported a position in Core Laboratories in Q3 2021 and held it in 4 quarters.
  • Cypress Capital's Core Laboratories position peaked at $466K in Q1 2022.
  • 162 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2022.

Based on Cypress Capital's 13F filing for Q3 2022, filed 1 Feb 2023.